Higher in vivo protein binding of etoposide in children compared with adult cancer patients

Cancer Letters

Volumn 106, Issue 1, 1996, Pages 97-100

  Liliemark, Eva ^a   Söderhäll, Stefan ^a   Sirzea, Florin ^a   Gruber, Astrid ^a   Ösby, Eva ^a   Björkholm, Magnus ^a   Zhou, Rong ^a   Peterson, Curt ^a   Liliemark, Jan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Children; Etoposide; High performance liquid chromatography; Leukemia; Protein binding; Small cell lung cancer; Ultrafiltration

Indexed keywords

ETOPOSIDE; SERUM ALBUMIN; TENIPOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG UPTAKE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; LUNG SMALL CELL CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT HISTIOCYTOSIS; MULTIPLE MYELOMA; OLIGODENDROGLIOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TEMPERATURE; ULTRAFILTRATION;

EID: 0030598978     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/0304-3835(96)04308-X     Document Type: Article

References (12)

1. [1] Belani, C., Doyle, L. and Aisner, J. (1994) Etoposide: current status and future perspectives in the management of malignant neoplasms. Cancer Chemother. Pharmacol., 34, S118-S126.
2. [2] Allen, L. and Creaven, P. (1975) Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivatives. Eur. J. Cancer, 11, 697-707.
3. [3] Stewart, C., Pieper, J., Arbuck, S. and Evans, W. (1989) Altered protein binding of etoposide in patients with cancer. Clin. Pharmacol. Ther., 45, 49-55.
4. [4] Stewart, C., Arbuck, S., Fleming, R. and Evans, W. (1990) Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. J. Clin. Oncol., 8, 1874-1879.
5. [5] Souich, P.d., Verges, J. and Erill, S. (1993) Plasma protein binding and pharmacological response. Clin. Pharmacokinet., 24, 435-440.
6. [6] Stewart, C., Arbuck, S., Fleming, R. and Evans, W. (1991) Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin. Pharmacol. Ther., 50, 385-393.
7. [7] Liliemark, E., Herngren, L., Pettersson, B., Peterson, C. and Liliemark, J. (1996) Ultrafiltration and subsequent high performance, liquid chromatography for in vivo determination of the protein binding of etoposide. Cancer Lett., in press.
8. [8] Liliemark, E.K., Liliemark, J., Peterson, B., Gruber, A., Björkholm, M. and Peterson, C. (1993) In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia: relation to plasma concentrations and protein binding. Leukemia Lymphoma, 10, 323-328.
9. [9] Liliemark, E., Pettersson, B., Peterson, C. and Liliemark, J. (1995) High-performance liquid chromatography with fluorometric detection for monitoring of etoposide and its cis-isomer in plasma and leukemic cells. J. Chromatogr. B: Biomed. Appl., 669, 311-317.
10. [10] Schwinghammer, T., Fleming, R., Rosenfeld, C., Przepiorka, D., Shadduck, R., Bloom, E. and Stewart, C. (1993) Disposition of total and unbound etoposide following high-dose therapy. Cancer Chemother. Pharmacol., 32, 273-278.
11. [11] Whitlam, J. and Brown, K. (1980) Ultrafiltration in serum protein binding determinations. J. Pharm. Sci., 70, 146-150.
12. [12] Crom, W., Glynn-Barnhart, A., Rodman, J., et al. (1987) Pharmacokinetics of anticancer drugs in children. Clin. Pharmacokinet., 12, 168-213.